Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase

Vincenzo Bronte, Sara Cingarlini, Elisa Apolloni, Paolo Serafini, Ilaria Marigo, Carmela De Santo, Beatrice Macino, Oriano Marin, Paola Zanovello

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Endogenous retrovirus (ERV) products are recognized by T lymphocytes in mice and humans. As these Ags are preferentially expressed by neoplastic tissues, they might represent an ideal target for active immunization by genetic vaccination. However, i.m. inoculation of plasmid DNA encoding mouse gp70 or p15E, two products of the env gene of an endogenous murine leukemia virus, elicited a weak Ag-specific T lymphocyte response and resulted in partial protection from challenge with mouse tumors possessing these Ags. Depletion experiments showed that CD8+, but not CD4+, T lymphocytes were crucial for the antitumor activity of the vaccines. Systemic administration of agonistic anti-CD40 mAb increased the therapeutic potential of genetic vaccination, but only when given during the tumor rejection phase and not at the time of immunization. This effect correlated with a dramatic increase in the number of ERV-specific CD8+ T lymphocytes. Adjuvant activity of CD40 agonists thus seems to be relevant to enhance the CD8 + T cell-dependent response in tumor-bearing hosts, suggesting that sustaining tumor-specific T lymphocyte survival in subjects undergoing vaccination might be a key event in the successful vaccination with weak tumor Ags.

Original languageEnglish
Pages (from-to)6396-6405
Number of pages10
JournalJournal of Immunology
Volume171
Issue number12
StatePublished - Dec 15 2003
Externally publishedYes

Fingerprint

Neoplasm Antigens
Vaccination
T-Lymphocytes
Endogenous Retroviruses
Neoplasms
env Gene Products
Murine Leukemia Viruses
Immunization
Plasmids
Vaccines
DNA

ASJC Scopus subject areas

  • Immunology

Cite this

Bronte, V., Cingarlini, S., Apolloni, E., Serafini, P., Marigo, I., De Santo, C., ... Zanovello, P. (2003). Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase. Journal of Immunology, 171(12), 6396-6405.

Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase. / Bronte, Vincenzo; Cingarlini, Sara; Apolloni, Elisa; Serafini, Paolo; Marigo, Ilaria; De Santo, Carmela; Macino, Beatrice; Marin, Oriano; Zanovello, Paola.

In: Journal of Immunology, Vol. 171, No. 12, 15.12.2003, p. 6396-6405.

Research output: Contribution to journalArticle

Bronte, V, Cingarlini, S, Apolloni, E, Serafini, P, Marigo, I, De Santo, C, Macino, B, Marin, O & Zanovello, P 2003, 'Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase', Journal of Immunology, vol. 171, no. 12, pp. 6396-6405.
Bronte, Vincenzo ; Cingarlini, Sara ; Apolloni, Elisa ; Serafini, Paolo ; Marigo, Ilaria ; De Santo, Carmela ; Macino, Beatrice ; Marin, Oriano ; Zanovello, Paola. / Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase. In: Journal of Immunology. 2003 ; Vol. 171, No. 12. pp. 6396-6405.
@article{0050efa7a7304ff1bc8a9ca68a4e4e44,
title = "Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase",
abstract = "Endogenous retrovirus (ERV) products are recognized by T lymphocytes in mice and humans. As these Ags are preferentially expressed by neoplastic tissues, they might represent an ideal target for active immunization by genetic vaccination. However, i.m. inoculation of plasmid DNA encoding mouse gp70 or p15E, two products of the env gene of an endogenous murine leukemia virus, elicited a weak Ag-specific T lymphocyte response and resulted in partial protection from challenge with mouse tumors possessing these Ags. Depletion experiments showed that CD8+, but not CD4+, T lymphocytes were crucial for the antitumor activity of the vaccines. Systemic administration of agonistic anti-CD40 mAb increased the therapeutic potential of genetic vaccination, but only when given during the tumor rejection phase and not at the time of immunization. This effect correlated with a dramatic increase in the number of ERV-specific CD8+ T lymphocytes. Adjuvant activity of CD40 agonists thus seems to be relevant to enhance the CD8 + T cell-dependent response in tumor-bearing hosts, suggesting that sustaining tumor-specific T lymphocyte survival in subjects undergoing vaccination might be a key event in the successful vaccination with weak tumor Ags.",
author = "Vincenzo Bronte and Sara Cingarlini and Elisa Apolloni and Paolo Serafini and Ilaria Marigo and {De Santo}, Carmela and Beatrice Macino and Oriano Marin and Paola Zanovello",
year = "2003",
month = "12",
day = "15",
language = "English",
volume = "171",
pages = "6396--6405",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase

AU - Bronte, Vincenzo

AU - Cingarlini, Sara

AU - Apolloni, Elisa

AU - Serafini, Paolo

AU - Marigo, Ilaria

AU - De Santo, Carmela

AU - Macino, Beatrice

AU - Marin, Oriano

AU - Zanovello, Paola

PY - 2003/12/15

Y1 - 2003/12/15

N2 - Endogenous retrovirus (ERV) products are recognized by T lymphocytes in mice and humans. As these Ags are preferentially expressed by neoplastic tissues, they might represent an ideal target for active immunization by genetic vaccination. However, i.m. inoculation of plasmid DNA encoding mouse gp70 or p15E, two products of the env gene of an endogenous murine leukemia virus, elicited a weak Ag-specific T lymphocyte response and resulted in partial protection from challenge with mouse tumors possessing these Ags. Depletion experiments showed that CD8+, but not CD4+, T lymphocytes were crucial for the antitumor activity of the vaccines. Systemic administration of agonistic anti-CD40 mAb increased the therapeutic potential of genetic vaccination, but only when given during the tumor rejection phase and not at the time of immunization. This effect correlated with a dramatic increase in the number of ERV-specific CD8+ T lymphocytes. Adjuvant activity of CD40 agonists thus seems to be relevant to enhance the CD8 + T cell-dependent response in tumor-bearing hosts, suggesting that sustaining tumor-specific T lymphocyte survival in subjects undergoing vaccination might be a key event in the successful vaccination with weak tumor Ags.

AB - Endogenous retrovirus (ERV) products are recognized by T lymphocytes in mice and humans. As these Ags are preferentially expressed by neoplastic tissues, they might represent an ideal target for active immunization by genetic vaccination. However, i.m. inoculation of plasmid DNA encoding mouse gp70 or p15E, two products of the env gene of an endogenous murine leukemia virus, elicited a weak Ag-specific T lymphocyte response and resulted in partial protection from challenge with mouse tumors possessing these Ags. Depletion experiments showed that CD8+, but not CD4+, T lymphocytes were crucial for the antitumor activity of the vaccines. Systemic administration of agonistic anti-CD40 mAb increased the therapeutic potential of genetic vaccination, but only when given during the tumor rejection phase and not at the time of immunization. This effect correlated with a dramatic increase in the number of ERV-specific CD8+ T lymphocytes. Adjuvant activity of CD40 agonists thus seems to be relevant to enhance the CD8 + T cell-dependent response in tumor-bearing hosts, suggesting that sustaining tumor-specific T lymphocyte survival in subjects undergoing vaccination might be a key event in the successful vaccination with weak tumor Ags.

UR - http://www.scopus.com/inward/record.url?scp=0346366992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346366992&partnerID=8YFLogxK

M3 - Article

VL - 171

SP - 6396

EP - 6405

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -